[MK TEST DO NOT TOUCH] American College of Cardiology's Annual Scientific Session & Expo 2022 (ACC.22)

[MK TEST DO NOT TOUCH] Post-TAVR SLT risk does not differ with edoxaban or DAPT

Finerenone reduces CV events, renal outcomes in T2D-related CKD

A pooled analysis of 13,171 patients from both the FIDELIO-DKD and FIGARO-DKD trials has confirmed the beneficial effects of finerenone, according to results of FIDELITY study, presented at the recently concluded American College of Cardiology Annual Scientific Session (ACC 2022).

[MK TEST DO NOT TOUCH] Canakinumab keeps adverse cardiac events at bay

Among patients with a history of myocardial infarction (MI) and elevated levels of high-sensitivity C-reactive protein (hsCRP), canakinumab effectively prevents the occurrence of adverse cardiac events over nearly 4 years, according to results of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), as presented in the recently concluded American College of Cardiology Annual Scientific Session (ACC 2022).

Real-time EHR-based alerts optimize treatment for heart failure

The use of the electronic health record (EHR) to provide timely, personalized clinical decision support alerts can improve the adoption of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) in the outpatient setting, as shown in the results of the PROMPT-HF trial presented at the American College of Cardiology (ACC) meeting.

[MK TEST DO NOT TOUCH] Adding alirocumab to rosuvastatin reduces coronary plaque in patients with acute MI

Adding alirocumab to rosuvastatin led to a significantly reduced coronary plaque in noninfarct-related arteries in patients with acute myocardial infarction (MI), according to the PACMAN-AMI* trial presented at ACC 2022.